MedTrace Logo

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2020-12-24

No results posted yet for this study

Summary

This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.

Conditions

  • Dyskinesias
  • Drug-induced

Interventions

DRUG

AQW051

Patients will receive AQW051 in a high dose once daily orally for 28 days.

DRUG

AQW051

Patients will receive AQW051 in a low dose once daily orally for 28 days.

DRUG

Placebo

Patients will receive placebo once daily orally for 28 days.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-15
Primary Completion
2013-02-21
Completion
2013-02-21
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01474421 on ClinicalTrials.gov